Piper Sandler raises Illumina price target to $200 on clinical strength

Key Facts

As the gene-sequencing market shifts toward clinical diagnostics, Illumina's growing presence in hospitals and labs reduces its reliance on volatile academic research budgets. Piper Sandler raised its price target for Illumina (ILMN) to $200 from $170, maintaining an Overweight rating, according to a report cited by Investing.com. The analyst highlighted strong clinical business momentum as the primary catalyst for the upgrade.

Per Piper Sandler's analysis, Illumina's clinical consumables grew 20% year-over-year in Q1 2026, driven by the NovaSeq X platform's dominance in high-throughput sequencing. This growth helps decouple Illumina from fluctuating academic funding and provides a more predictable revenue stream. The robust demand from hospitals and clinics bolsters analyst confidence in the company's growth trajectory.

Illumina shares closed at $175.83 on June 30, 2026, after trading between a high of $181 and a low of $174.78 during the session. The new $200 price target implies roughly 13.8% upside from current levels. Investors will watch upcoming Q2 results for further evidence of clinical adoption and potential margin expansion from the NovaSeq X ramp.